Skip to content

Clinical trials

Phase 3 Schizophrenia trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Schizophrenia Phase: Phase 3 Country / region: United States Clear all

190 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20024
20034
200411
200510
200614
20078
200810
20092
201013
201112
20129
201315
20143
20154
20168
20178
20182
20197
20202
202111
20227
20236
20243
20256
20267

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed145
Terminated23
Recruiting17
Active, not recruiting2
Withdrawn2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Otsuka Pharmaceutical Development & Commercialization, Inc.29
Alkermes, Inc.12
Sumitomo Pharma America, Inc.12
Karuna Therapeutics, Inc., a Bristol Myers Squibb company10
H. Lundbeck A/S7
Eli Lilly and Company6
Hoffmann-La Roche6
Neurocrine Biosciences6
AstraZeneca5
Forest Laboratories5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Schizophrenia190
Psychotic Disorders36
Mental Disorders12
Bipolar Disorder7
Cognition Disorders3
Mania3
Psychomotor Agitation3
Anxiety Disorders2
Autism Spectrum Disorder2
Autistic Disorder2

Trials

Showing 1 to 25 of 190. Each trial links to its page on Pharma Observatory.

90 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.